ArticleInternal medicine journal2025
Incidence, prevalence and mortality of rheumatoid arthritis in Canterbury, Aotearoa New Zealand.
Article in Internal medicine journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThere is relatively little research regarding the frequency of rheumatoid arthritis (RA) in Canterbury and no previous studies comparing the mortality of RA in Aotearoa New Zealand to a general population.
aimsTo determine the incidence, prevalence and mortality of RA in Canterbury, Aotearoa New Zealand.
methodsClinical records of persons attending the Christchurch Hospital rheumatology service between 1 January 2006 and 31 December 2008 (Period 1) and between 1 January 2011 and 31 December 2013 (Period 2) were reviewed to identify individuals who met the 2010 American College of Rheumatology/European League Against Rheumatism RA classification criteria. Medical records for persons treated by private sector rheumatologists were also reviewed. The period prevalence and average annual incidence for each time period were calculated. Prevalence and incidence rates for the total population were age- and sex-adjusted based on the usually resident population from the 2013 national Census. Standardised mortality ratios (SMRs) compared to the general population were calculated.
resultsThe annual incidence was 24.40 per 100 000 (95% confidence interval (CI): 21.36-27.43) for Period 1 and 22.06 per 100 000 (95% CI: 19.32-24.81) for Period 2. The period prevalence was 442.65 per 100 000 (95% CI: 420.08-465.04) for Period 1 and 448.66 per 100 000 (95% CI: 427.31-470.01) for Period 2. The all-cause SMR for individuals with incident RA was 1.25 (95% CI: 0.95-1.60). The SMR for all prevalent RA during Period 1 was 2.01 (95% CI: 1.85-2.19) and for Period 2 was 1.87 (95% CI: 1.69-2.06).
conclusionsThe frequency of RA in the Canterbury population is comparable to other regions. Mortality for all individuals with prevalent RA was approximately two times higher than the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.